We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment ... Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.325 | -10.0619195046 | 3.23 | 3.34 | 2.675 | 374811 | 2.88670262 | CS |
4 | -0.175 | -5.68181818182 | 3.08 | 3.94 | 2.52 | 492644 | 3.20418136 | CS |
12 | 0.065 | 2.28873239437 | 2.84 | 3.94 | 2.39 | 345641 | 3.14871092 | CS |
26 | -2.305 | -44.2418426104 | 5.21 | 6.06 | 2.39 | 468176 | 4.06440376 | CS |
52 | -6.265 | -68.320610687 | 9.17 | 20.71 | 2.13 | 686657 | 8.51575367 | CS |
156 | -12.595 | -81.2580645161 | 15.5 | 20.71 | 2.13 | 594976 | 8.7363767 | CS |
260 | -12.595 | -81.2580645161 | 15.5 | 20.71 | 2.13 | 594976 | 8.7363767 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions